Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 312.50 | 200.50 | 266.00 | 379.00 | 0.7019 | 0.3603 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 254.00 | 379.00 | 0.6702 | 0.2937 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 335.00 | 379.00 | 0.8839 | 0.7486 | |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 230.00 | 379.00 | 0.6069 | 0.1612 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 299.00 | 379.00 | 0.7889 | 0.5450 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 354.00 | 379.00 | 0.9340 | 0.8568 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 505.00 | 379.00 | 1.3325 | 1.7336 |
| SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 312.50 | 200.50 | 390.00 | 379.00 | 1.0290 | 1.0633 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 9 | 312.50 | 200.50 | 278.00 | 379.00 | 0.7335 | 0.4273 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 526.00 | 379.00 | 1.3879 | 1.8575 | |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 9 | 312.50 | 200.50 | 452.00 | 379.00 | 1.1926 | 1.4227 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 372.00 | 379.00 | 0.9815 | 0.9598 | |
| SK-BR-3 | Linsitinib | 0.01 | uM | 9 | 312.50 | 200.50 | 517.00 | 379.00 | 1.3641 | 1.8043 |
| SK-BR-3 | 17-AAG | 0.1 | uM | 9 | 312.50 | 200.50 | 138.00 | 379.00 | 0.3641 | -0.3341 |
| SK-BR-3 | Lapatinib | 0.01 | uM | 9 | 312.50 | 200.50 | 350.00 | 379.00 | 0.9235 | 0.8340 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 235.00 | 379.00 | 0.6201 | 0.1887 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 9 | 312.50 | 200.50 | 161.00 | 379.00 | 0.4248 | -0.2125 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 312.50 | 200.50 | 365.00 | 379.00 | 0.9631 | 0.9197 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 451.00 | 379.00 | 1.1900 | 1.4169 | |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 264.00 | 379.00 | 0.6966 | 0.3492 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 233.00 | 379.00 | 0.6148 | 0.1777 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 312.50 | 200.50 | 439.00 | 379.00 | 1.1583 | 1.3470 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 312.50 | 200.50 | 167.00 | 379.00 | 0.4406 | -0.1805 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 283.00 | 379.00 | 0.7467 | 0.4552 | |
| SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 857.00 | 929.25 | 0.9223 | 0.8656 |